AstraZeneca buying drug developer Alexion for $39 billion - Boston.com

ponjotor.blogspot.com

AP

December 12, 2020 | 12:10 PM

LONDON (AP) — Pharmaceutical company AstraZeneca says it is buying U.S. drug developer Alexion in a deal worth $39 billion.

Cambridge, England-based AstraZeneca PLC, which is involved in one of the efforts to develop a COVID-19 vaccine, said Saturday it’s using a combination of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals Inc.

The boards of both companies unanimously approved the transaction, which still needs regulatory and shareholder approval. The deal is expected to close in the third quarter of 2021.

“This acquisition allows us to enhance our presence in immunology,” AstraZeneca CEO Pascal Soriot said in a statement.

Advertisement

AstraZeneca and Oxford University have jointly developed a coronavirus vaccine that British and Canadian regulators are assessing, alongside a rival effort by U.S. drugmaker Pfizer and Germany’s BioNTech that has already earned some emergency approvals, and another by U.S. biotechnology company Moderna.

Get Boston.com's browser alerts:

Enable breaking news notifications straight to your internet browser.

Turn on notifications

Great, you’re signed up!

Let's block ads! (Why?)

Business - Latest - Google News
December 13, 2020 at 12:10AM
https://ift.tt/3qVajXJ

AstraZeneca buying drug developer Alexion for $39 billion - Boston.com
Business - Latest - Google News
https://ift.tt/2Rx7A4Y


Bagikan Berita Ini